Revital Gabinet Kardiologiczny s.c. NZOZ Revital Kardiologia
- Address
- Ul. Ziolowa 68, 40-635 Katowice, Poland
Revital Gabinet Kardiologiczny - Cardiovascular Research Center
Revital Gabinet Kardiologiczny s.c. NZOZ Revital Kardiologia is a specialized cardiology research center dedicated to advancing the treatment of cardiovascular conditions through participation in innovative clinical trials. The center focuses on developing novel therapeutic approaches for patients with complex cardiac arrhythmias and cardiovascular disorders.
- Atrial fibrillation management in high-risk patient populations
- Advanced anticoagulation strategies and stroke prevention
- Novel therapeutic interventions for patients unsuitable for conventional oral anticoagulation
The center demonstrates particular expertise in conducting Phase 3 multicenter trials evaluating cutting-edge treatments for atrial fibrillation, with special emphasis on high-risk patients who present unique therapeutic challenges. Their research contributes to addressing critical unmet medical needs in patients deemed unsuitable for standard oral anticoagulation therapy, focusing on reducing the risk of ischemic stroke and systemic embolic events through innovative pharmacological approaches.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Anthos Therapeutics Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Revital Gabinet Kardiologiczny s.c. NZOZ Revital Kardiologia
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of Budiodarone in Subjects with Non-permanent Atrial Fibrillation | Xyra LLC | Phase IV | Recruiting | Jul 2026 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abelacimab | 1 | Unknown | 2023-10-31 | 2023-10-31 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.